The research team has already found that preserving lymph nodes during treatment initiation helps the body's immune system ...

Head and neck cancers remain one of the most significant global health challenges. According to the latest data, in 2023 ...

Since immunotherapy has been approved by the Food and Drug Administration to treat advanced head and neck cancer (HNC), it has offered patients new ...

RT-NBTXR3 followed by anti-PD-1 demonstrated favorable safety profile, disease control and tumor response in patients both ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data for the novel, potential ...

Telehealth respiratory group Respiri says a sales deal with a US group will help the firm achieve cash-flow breakeven status ...

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in ...

Oncologists are perturbed by the increase in early-onset tumors and the potential role of lifestyle, though this may not ...

Esophageal Cancer: Phase 1 study (NCT04615013 ... randomized Phase 3 study in locally advanced head and neck squamous cell cancers. In February 2020, the United States Food and Drug Administration ...

Read this article to learn about supporting palliative care patients and their families with eating and drinking concerns.

ORRs of 54.8% and 50.0% achieved in locally advanced and metastatic cSCC, with median follow-up durations of 24.1 and 29.3 months, respectively. Results demonstrate a deepening of response over time, ...